Diabetes and endogenous orphanin FQ/nociceptin levels in rat CSF and plasma

International Journal of Diabetes and Metabolism

Volumn 13, Issue 3, 2005, Pages 147-153

  Tekes, Kornélia ^a   Hantos, Mónika ^a   Gyenge, Melinda ^a   Bizderi, Borbála ^a   Kecskeméti, Valéria ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Ageing; Diabetes mellitus; Neuropathic pain; OrphaninFQ nociception; Radioimmunoassay; Rat

Indexed keywords

GLUCOSE; NOCICEPTIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL FUNCTION; CEREBROSPINAL FLUID; CLINICAL FEATURE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; RAT;

EID: 33751219529     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: 10.1159/000497583     Document Type: Article

References (51)

1. Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett 1994; 34: 33-38.
2. Neal CR Jr, Mansour A, Reinscheid R, et al. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)1-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 1999; 412: 563-605.
3. Bridge KE, Wainwright A, Reilly K, Oliver KR. Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience 2003; 118: 513-523.
4. Peluso J, LaForge KS, Matthes HW, et al. Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J Neuroimmunol 1998; 81: 184-192.
5. Witta J, Palkovits M, Rosenberger J, Cox BM. Distribution of nociceptin/orphanin FQ in adult human brain. Brain Res 2004; 997: 24-29.
6. 35S]GTS gamma S binding in rat brain. Neuro Report 1996; 7: 729-733.
7. Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor. Peptides 2000; 21: 907-917.
8. Clarke S, Chen ZP, Hsu MS, et al. Quantitative autoradiographic mapping of the ORL1, mu, delta and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene. Brain Res 2001; 906: 13-24.
9. Moran TD, Abdulla FA, Smith PA. Cellular neurophysiological actions of nociceptin/orphanin FQ. Peptides 2000; 21: 969-976.
10. Houtani T, Nishi M, Takeshima H, et al. Structure and Regional Distribution of Nociceptin/OrphaninFQ Precursor. Biochem Biophys Res Commun 1996; 219: 714-719.
11. Darland T, Heinricher MM, Grandy DK. Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 1998; 21: 215-221.
12. Jenck F, Wichmann J, Moreau FM, et al. A synthetic agonist at the orphaninFQ/nociceptin receptor ORL1 anxiolytic profile in the rat. Proc Natl Acad Sci USA 2000; 97: 4938-4943.
13. Saito Y, Maruyama K, Kawano H, et al. Molecular cloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule. J Biol Chem 1996; 271: 156-159.
14. Saito Y, Maruyama K, Saido TC, Kawashima S. Overexpression of a neuropeptide nociceptin/orphanin FQ gene, N23K/N27K, induces neurite outgrowth in mouse NS20Y cells. J Neurosci Res 1997; 48: 37-42.
15. Buzas B, Rosenberger J, Kim KW, Cox BM. Inflammatory mediators increase the expression of Nociceptin/Orphanin in rat astrocytes in culture. Glia 2002; 39: 237-246.
16. Okuda-Ashitaka E, Minami T, Tachibana S, et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 1998; 392: 286-289.
17. Allen RG, Peng B, Pellegrino MJ, et al. Altered processing of pro-orphaninFQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. J Neurosci 2001; 21: 5864-5870.
18. Noble F, Roques BP. Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in mice. FEBS Lett 1997; 401: 227-229.
19. Courteix C, Coudoré-Civiale M-A, Privat A-M, et al. Evidence for an exclusive antinococeptive effect of nociceptin/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain. Pain 2004; 110: 236-245.
20. Luo C, Kumamoto E, Fume H, et al. Nociceptin inhibits excitatory but not inhibitory transmission to substantia gelatinosa neurons of adult rat spinal cord. Neuroscience 2002; 109: 349-358.
21. Briscini L, Corradini L, Ongini E, Bertorelli R. Up-regulation of ORL1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur J Neurosci 2002; 16: 1705-1712.
22. Bertorelli R, Bastia E, Citterio F, et al. Lack of the nociceptin receptor does nor affect acute or chronic nociception in mice. Peptides 2002; 23: 1589-1596.
23. Nakagawa T, Kaneko M, Inamura S, Satoh M. Intracerebroventricular administration of nocistatin reduces inflammatory hyperalgesia in rats. Neurosci Lett 1999; 265: 64-66.
24. Helyes Z, Nemeth J, Pinter E, Szolcsanyi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol 1997; 121: 613-615.
25. Inoue M, Kawashima T, Allen RG, Ueda H. Nocistatin and prepro-nociceptin/orphanin FQ 160-187 cause nociception through activation of Gi/o in capsaicin-sensitive and of Gs in capsaicin-insensitive nociceptors, respectively. J Pharmacol Exp Ther 2003; 306: 141-146.
26. Devine DP, Watson SJ, Akil H. Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic-hypothalamic-pituitary-adrenal axis. Neuroscience 2001; 102: 541-553.
27. Nicholson JR, Akil H, Watson SJ. OrphaninFQ-induced hyperphagia is mediated by corticosterone and central glucocorticoid receptors. Neuroscience 2002; 115: 637-643.
28. Bryant W, Janik J, Baumann M, Callahan P. Orphanin FQ stimulates prolactin and growth hormone release in male and female rats Brain Res 1998; 807: 228-233.
29. Netti C, Rapetti D, Sibilia V et al. Endocrine effects of centrally injected nociceptin in the rat. Brain Res 2002; 938: 55-61.
30. Lindholm S, Ploj K, Franck J, Nylander I. Nociceptin/orphanin FQ tissue concentration in the rat brain. Effects of repeated ethanol administration at various post-treatment intervals. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 303-306.
31. Dassesse D, Ledent C, Meunier J-C, et al. Regulation of nociceptin mRNA expression in the septum by dopamine and adenosine systems. NeuroReport 2000; 11: 3243-3246.
32. Ploj K, Roman E, Bergström L, Nylander I. Effects of neonatal handling on nociceptin/orphanin FQ and opioid peptide levels in female rats. Pharmacol Biochem Behav 2001; 69: 173-179.
33. Armstead WM. Age-dependent vasopressinergig modulation of NOC/oFQ-induced impairment of NMDA cerebrovasodilation after brain injury. J Neurotrauma 2001; 18: 615-623
34. Poitout V, Robertson RP. An integrated view of beta cell dysfunction in type-II diabetes. Annu Rev Med 1996; 47: 69-83.
35. Josefsen K, Buschard K, Sorensen R, et al. Glucose stimulation of pancreatic β-cell lines induces expression and secretion of dynorphin. Endocrinology 1998; 139: 4329-4336.
36. Adeghate E., Ponery AS. The role of leucine-enkephalin on insulin and glucagons secretion from pancreatic tissue fragments of normal and diabetic rats. Arch Physiol Biochem 2001; 109: 223-229.
37. Courteix C, Eschalier A, Lavarenne J. Streptozotocin-induced diabetic rats: behavioral evidence for a model of chronic pain. Pain 1993; 53: 81-88.
38. Kamei J, Ohsawa M, Kashiwazaki T, Nagase H. Antinociceptive effects of the ORL1 receptor agonist nociceptin/orphanin FQ in diabetic mice. Eur J Pharmacol 1999; 370: 109-116.
39. Malan TP, Ossipov MH, Gardell LR, et al. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain 2000; 86: 185-194.
40. Nagamitsu S, Matsuishi T, Komori H, et al. Age-related changes in the cerebrospinal fluid level of beta-endorphin and substance P. J Neural Transm 1998; 105: 53-58.
41. Dax EM, Reichman C, Fullerton M, et al. Beta endorphin and dynorphin levels in rat pituitary and hypothalamus: age studies. Neuroendocrinology 1988; 47: 241-248.
42. Bigoni R, Giuliani S, Calo G, et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. N-Sch Arch Pharmacol 1999; 359: 160-167.
43. Thai L, Hong JS, Wiley RG, Gallagher M. The regulation of hippocampal dynorphin by neural/neuroendocrine pathways: models for effects of aging on an opioid peptide system. Neuroscience 1996; 70: 661-671.
44. Kalra SP, Sahu A, Kalra PS: Ageing of the neuropeptidergic signals in rats. J Reproduc Fertil Suppl. 1993; 46: 11-19.
45. Hantos M, Szalay F, Lakatos PL, et al. Elevated plasma nociceptin level in patients with Wilson disease. Brain Res Bull 2002; 58: 311-313.
46. deGandarias JM, Irazusta J, Echevarria E, Gil J, Casis L. Age-related changes in the soluble and the membrane-bound Tyr-aminopeptidase activities in several areas of the male and female rat brain. Reprod Fertil Dev 1996; 8: 465-469.
47. Forman LJ, Lewis SEM, Vasilenko P. Streptozotocin diabetes alters immunoreactive β-endorphin levels and pain perception after 8 weeks in female rats. Diabetes 1986; 35: 1309-1313.
48. Lee JH and McCarty RC: Glycemic control of pain threshold in diabetic and control rats. Physiol Behav 1990; 47: 225-230.
49. Raz I, Hasdai D, Seltzer Z, Melmed RN. Effects of hyperglycemia in pain perception and on efficacy of morphine analgesia in rats. Diabetes 1988; 37: 1253-1259.
50. Sun R-Q, Wang Y, Zhao C-S, et al. Changes in brain content of nociceptin/orphaninFQ and endomorphin 2 in a rat model of neuropathic pain. Neurosci Lett 2001; 311: 13-16.
51. Rosen A, Lundeberg T, Bytner B, Nylander I. Central changes in nociceptin, dynorphin B and Metenkephalin-Arg-Phe in different models of nociception. Brain Res 2000: 857; 212-218.